Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts.

Body, R, Carlton, E, Sperrin, M, Lewis, PS, Burrows, G, Carley, S, McDowell, G, Buchan, I, Greaves, K and Mackway-Jones, K (2016) Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts. Emergency Medicine Journal, 34 (6). pp. 349-356. ISSN 1472-0205

[img]
Preview
Text
Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid single biomarker re-derivation and external validati.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (645kB) | Preview

Abstract

BACKGROUND: The original Manchester Acute Coronary Syndromes model (MACS) 'rules in' and 'rules out' acute coronary syndromes (ACS) using high sensitivity cardiac troponin T (hs-cTnT) and heart-type fatty acid binding protein (H-FABP) measured at admission. The latter is not always available. We aimed to refine and validate MACS as Troponin-only Manchester Acute Coronary Syndromes (T-MACS), cutting down the biomarkers to just hs-cTnT. METHODS: We present secondary analyses from four prospective diagnostic cohort studies including patients presenting to the ED with suspected ACS. Data were collected and hs-cTnT measured on arrival. The primary outcome was ACS, defined as prevalent acute myocardial infarction (AMI) or incident death, AMI or coronary revascularisation within 30 days. T-MACS was built in one cohort (derivation set) and validated in three external cohorts (validation set). RESULTS: At the 'rule out' threshold, in the derivation set (n=703), T-MACS had 99.3% (95% CI 97.3% to 99.9%) negative predictive value (NPV) and 98.7% (95.3%-99.8%) sensitivity for ACS, 'ruling out' 37.7% patients (specificity 47.6%, positive predictive value (PPV) 34.0%). In the validation set (n=1459), T-MACS had 99.3% (98.3%-99.8%) NPV and 98.1% (95.2%-99.5%) sensitivity, 'ruling out' 40.4% (n=590) patients (specificity 47.0%, PPV 23.9%). T-MACS would 'rule in' 10.1% and 4.7% patients in the respective sets, of which 100.0% and 91.3% had ACS. C-statistics for the original and refined rules were similar (T-MACS 0.91 vs MACS 0.90 on validation). CONCLUSIONS: T-MACS could 'rule out' ACS in 40% of patients, while 'ruling in' 5% at highest risk using a single hs-cTnT measurement on arrival. As a clinical decision aid, T-MACS could therefore help to conserve healthcare resources.

Item Type: Article
Uncontrolled Keywords: 1103 Clinical Sciences, 1110 Nursing, 1117 Public Health and Health Services
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: BMJ Publishing Group
Related URLs:
Date Deposited: 06 Apr 2020 09:23
Last Modified: 06 Apr 2020 09:30
DOI or Identification number: 10.1136/emermed-2016-205983
URI: http://researchonline.ljmu.ac.uk/id/eprint/12655

Actions (login required)

View Item View Item